Florbetaben F 18 injection(with Chinese trademark 歐韋寧?), an early diagnostic tool for Alzheimer’s disease, has been officially launched in hospitals across China, achieving GMP-standardized production and commercialization.
2024
Meilleur, an overseas affiliate, and its next-generation Aβ-PET imaging agent NAV-4694 for Alzheimer’s disease, have been acquired by the Nasdaq-listed company Lantheus.
Jiangsu Sinotau Pharmaceutical Co., Ltd., a subsidiary, has obtained a radioactive drug business license.
Sichuan Sinotau Pharmaceutical Co., Ltd., a wholly-owned subsidiary, has received the Radiation Safety License.
Sinotau is awarded the national “Specialized, Refined, and New ‘Little Giant’” enterprise title, highlighting our innovation capabilities and market competitiveness.
2023
Adenosine injection (with Chinese trademark歐達樂?) was approved for marketing.
Nasdaq-listed company Lantheus acquired Cerveau, a joint venture of Sinotau.
Closed a CNY ￥1.1bn financing round and the total financing amounts to CNY ￥2.6bn.
Florbetaben F 18 injection（with Chinese trademark 歐韋寧? and foreign trademark Neuraceq? was received regulatory approval from National Medical Products Administration (NMPA) in China, which is the first domestic radiopharmaceutical targeting β-amyloid approved to be used to support diagnosis of Alzheimer’s disease (AD).
2022
XTR006, an 18F-labeled PET imaging agent with a high-affinity to Tau protein developed for Alzheimer’s disease, received clinical approval.
The New Drug Application of Florbetaben F 18 injection was being accepted.
The first subject had been dosed in the Phase III clinical trial of lutetium Lu 177 dotatate, which is the first domestic targeted therapeutic radiopharmaceutical independently developed by Sinotau, on Sept.24, 2022.
Clinical trial application of [177Lu]Lu-XT033 injection was approved.
The single-photon emission computed tomography(SPECT) machine received registration certificate for medical device, becoming the first large professional equipment in the field of Chinese cardiac nuclear medicine to promote domestic production.
2021
Completed clinical trial of NeuraceqTM.
Completed Phase I clinical trial of XTR003 and XTR004, and initiated Phase II clinical trial.
Closed CNY ￥640m?series?D&D+ financing?round co-invested by CICC, China Life Private Equity, Centurium Capital and many other well-known investment institutions.
Achieve strategic collaboration with Biogen, JOINN, United Imaging, DualityBio respectively.
2020
Obtained clinical trial approval of class 1 new drugs XTR003 and XTR004.
Closed CNY?￥640m?series?D&D+ financing?round?co-invested by Hynergy Industrial Funds Management Co., Ltd., Sinopharm Capital, Lotus Lake Captital, Cash Capital and Winning Ventures.
2019
Obtained?clinical trial?approval?of NeuraceqTM.
2018
Obtained global authorization for a new drug for nuclear therapy of prostate cancer from the National Institutes of Health (NIH).
2017
Entered into a licensing agreement with Cerveau Technologies, Inc. for the rights to a Tau protein tracer in China.
Entered into a licensing agreement with Piramal Imaging SA for the rights to beta amyloid tracer NeuraceqTM in China.
Closed a CNY ￥150m series B financing round co-invested by Qiming Venture Partners and 3E Bioventures.
2016
Established Cerveau, a US joint venture.
Closed a CNY ￥130m series A financing round led by Winning Ventures.
2015
Sinotau USA Inc., a wholly owned subsidiary of Sinotau, was established in Boston.
2014
Started the research and development of radiopharmaceuticals.
